{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T04:44:41Z","timestamp":1790138681082,"version":"4.0.1"},"reference-count":43,"publisher":"Impact Journals, LLC","issue":"19","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,5,9]]},"DOI":"10.18632\/oncotarget.16141","type":"journal-article","created":{"date-parts":[[2017,3,11]],"date-time":"2017-03-11T23:51:58Z","timestamp":1489276318000},"page":"30644-30655","source":"Crossref","is-referenced-by-count":12,"title":["Paclitaxel synergizes with exposure time adjusted CD22-targeting immunotoxins against B-cell malignancies"],"prefix":"10.18632","volume":"8","author":[{"given":"Fabian","family":"M\u00fcller","sequence":"first","affiliation":[{"name":"Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA"},{"name":"Department of Hematology and Oncology, University Hospital Erlangen, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Stookey","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA"},{"name":"MD Program, University of North Caroline, Chapel Hill, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler","family":"Cunningham","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA"},{"name":"MD\/PhD Program, University of Miami, Miller School of Medicine, Miami, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira","family":"Pastan","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2017,3,11]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nrc1891","article-title":"Immunotoxin therapy of cancer","volume":"6","author":"Kreitman","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"2","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1182\/blood.V90.5.2020","article-title":"Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors","volume":"90","author":"FitzGerald","year":"1997","journal-title":"Blood"},{"key":"3","doi-asserted-by":"crossref","first-page":"6719","DOI":"10.1200\/JCO.2005.11.437","article-title":"Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies","volume":"23","author":"Pastan","year":"2005","journal-title":"J Clin Oncol"},{"key":"4","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1158\/1078-0432.CCR-09-2980","article-title":"Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial","volume":"16","author":"Pastan","year":"2010","journal-title":"Clin Cancer Res"},{"key":"5","first-page":"995","article-title":"Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display","volume":"8","author":"Pastan","year":"2002","journal-title":"Clin Cancer Res"},{"key":"6","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1200\/JCO.2011.38.1756","article-title":"Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia","volume":"30","author":"Pastan","year":"2012","journal-title":"J Clin Oncol"},{"issue":"19 Supplement","key":"7","first-page":"CT230","article-title":"Pediatric phase 1 trial of moxetumomab pasudotox: Activity in chemotherapy refractory acute lymphoblastic leukemia (ALL)","volume":"74","author":"Pastan","year":"2014","journal-title":"Cancer Res"},{"key":"8","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1182\/blood-2008-08-173195","article-title":"A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity","volume":"113","author":"Pastan","year":"2009","journal-title":"Blood"},{"key":"9","doi-asserted-by":"crossref","first-page":"11782","DOI":"10.1073\/pnas.1209292109","article-title":"Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes","volume":"109","author":"Pastan","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10","doi-asserted-by":"crossref","first-page":"E3597","DOI":"10.1073\/pnas.1218138109","article-title":"Identification and elimination of an immunodominant T-cell epitope in recombinant immunotoxins based on Pseudomonas exotoxin A","volume":"109","author":"Pastan","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"11","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1158\/1078-0432.CCR-15-0488","article-title":"Refining the mantle cell lymphoma paradigm: impact of novel therapies on current practice","volume":"21","author":"Goy","year":"2015","journal-title":"Clin Cancer Res"},{"key":"12","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1470-2045(15)00438-6","article-title":"Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial","volume":"17","author":"Nomie","year":"2016","journal-title":"Lancet Oncol"},{"key":"13","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S0140-6736(15)00667-4","article-title":"Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study","volume":"387","author":"Cho","year":"2016","journal-title":"Lancet"},{"key":"14","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1002\/cncr.25792","article-title":"Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma","volume":"117","author":"Blum","year":"2011","journal-title":"Cancer"},{"key":"15","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S1470-2045(11)70150-4","article-title":"Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial","volume":"12","author":"Esseltine","year":"2011","journal-title":"Lancet Oncol"},{"key":"16","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa1412096","article-title":"Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma","volume":"372","author":"Drach","year":"2015","journal-title":"N Engl J Med"},{"key":"17","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.1200\/JCO.2013.49.2835","article-title":"Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study","volume":"31","author":"Witzig","year":"2013","journal-title":"J Clin Oncol"},{"key":"18","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S1470-2045(12)70200-0","article-title":"Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1\/2 clinical trial","volume":"13","author":"Newberry","year":"2012","journal-title":"Lancet Oncol"},{"key":"19","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1056\/NEJMoa1505237","article-title":"Lenalidomide plus Rituximab as initial treatment for mantle-cell lymphoma","volume":"373","author":"Leonard","year":"2015","journal-title":"N Engl J Med"},{"key":"20","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S1470-2045(11)70062-6","article-title":"Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study","volume":"12","author":"Witzig","year":"2011","journal-title":"Lancet Oncol"},{"issue":"11","key":"21","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1200\/JCO.2015.63.5904","article-title":"Mantle cell lymphoma","volume":"34","author":"Wang","year":"2016","journal-title":"J Clin Oncol"},{"key":"22","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1182\/blood-2014-05-521898","article-title":"Mantle cell lymphoma: evolving management strategies","volume":"125","author":"Rule","year":"2015","journal-title":"Blood"},{"key":"23","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1038\/leu.2014.171","article-title":"How to manage mantle cell lymphoma","volume":"28","author":"Hermine","year":"2014","journal-title":"Leukemia"},{"key":"24","doi-asserted-by":"crossref","first-page":"4913","DOI":"10.1158\/1078-0432.CCR-15-2500","article-title":"Wide variability in the time required for immunotoxins to kill B lineage acute lymphoblastic leukemia cells: Implications for trial design","volume":"22","author":"Pastan","year":"2016","journal-title":"Clin Cancer Res"},{"key":"25","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1158\/0008-5472.CAN-15-2401","article-title":"Anticancer effects of mesothelin-targeted immunotoxin therapy are regulated by tyrosine kinase DDR1","volume":"76","author":"Pastan","year":"2016","journal-title":"Cancer Res"},{"key":"26","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1158\/1535-7163.MCT-15-0828","article-title":"Protein kinase inhibitor H89 enhances the activity of Pseudomonas exotoxin A-based immunotoxins","volume":"15","author":"Pastan","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"27","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1158\/1535-7163.MCT-13-0998","article-title":"ABT-737 promotes the dislocation of ER luminal proteins to the cytosol, including pseudomonas exotoxin","volume":"13","author":"FitzGerald","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"28","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1158\/1535-7163.MCT-14-0089-T","article-title":"andactivity of the low-immunogenic antimesothelin immunotoxin RG7787 in pancreatic cancer","volume":"13","author":"Pastan","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"29","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1158\/1535-7163.MCT-14-0132","article-title":"Efficacy of RG7787, a next-generation mesothelin-targeted immunotoxin, against triple-negative breast and gastric cancers","volume":"13","author":"Pastan","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"30","doi-asserted-by":"publisher","first-page":"9189","DOI":"10.18632\/oncotarget.13984","article-title":"Mesothelin-targeted immunotoxin RG7787 has synergistic anti-tumor activity when combined with taxanes","volume":"8","author":"Alewine","year":"2017","journal-title":"Oncotarget"},{"key":"31","doi-asserted-by":"crossref","first-page":"17099","DOI":"10.1073\/pnas.0708101104","article-title":"Immunotoxin, Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors","volume":"104","author":"Pastan","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"32","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/labinvest.2014.61","article-title":"Mouse models of mantle cell lymphoma, complex changes in gene expression and phenotype of engrafted MCL cells: implications for preclinical research","volume":"94","author":"Zivny","year":"2014","journal-title":"Lab Invest"},{"key":"33","doi-asserted-by":"crossref","unstructured":"Innocenti, Danesi, Di Paolo, Agen, Nardini, Bocci, Del Tacca. Plasma and tissue disposition of paclitaxel (taxol) after intraperitoneal administration in mice. Drug metabolism and disposition. 1995; 23:713\u2013717.","DOI":"10.1016\/S0090-9556(25)06648-6"},{"key":"34","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/pbc.25410","article-title":"Characterization of CD22 expression in acute lymphoblastic leukemia","volume":"62","author":"Wayne","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"35","article-title":"Combination of taxanes with mesothelin-targeted immunotoxin RG7787 induces synergistic killing of pancreatic cancer","volume":"75","author":"Pastan","year":"2015","journal-title":"AACR; Cancer Res"},{"key":"36","doi-asserted-by":"crossref","first-page":"3444","DOI":"10.1128\/MCB.00813-09","article-title":"Pseudomonas exotoxin A-mediated apoptosis is Bak dependent and preceded by the degradation of Mcl-1","volume":"30","author":"Pastan","year":"2010","journal-title":"Mol Cell Biol"},{"key":"37","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.1182\/blood-2002-09-2739","article-title":"Induction of tumor necrosis factor by bryostatin 1 is involved in synergistic interactions with paclitaxel in human myeloid leukemia cells","volume":"101","author":"Grant","year":"2003","journal-title":"Blood"},{"key":"38","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2007-09-078162","article-title":"Bcl-2-family proteins and hematologic malignancies: history and future prospects","volume":"111","author":"Reed","year":"2008","journal-title":"Blood"},{"key":"39","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1365-2141.2010.08251.x","article-title":"Cytotoxicity of the anti-CD22 immunotoxin HA22 (CAT-8015) against paediatric acute lymphoblastic leukaemia","volume":"150","author":"Pastan","year":"2010","journal-title":"Br J Haematol"},{"key":"40","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.devcel.2011.06.014","article-title":"Genome-wide RNAi screens identify genes required for Ricin and PE intoxications","volume":"21","author":"Bard","year":"2011","journal-title":"Dev Cell"},{"key":"41","doi-asserted-by":"crossref","first-page":"E1135","DOI":"10.1073\/pnas.1501958112","article-title":"Whole-genome RNAi screen highlights components of the endoplasmic reticulum\/Golgi as a source of resistance to immunotoxin-mediated cytotoxicity","volume":"112","author":"FitzGerald","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"42","first-page":"503","article-title":"Recombinant immunotoxins in the treatment of cancer","volume":"248","author":"Bera","year":"2004","journal-title":"Methods Mol Biol"},{"key":"43","doi-asserted-by":"crossref","first-page":"349","DOI":"10.4161\/mabs.19870","article-title":"Targeting malignant B cells with an immunotoxin against ROR1","volume":"4","author":"Rader","year":"2012","journal-title":"MAbs"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.16141","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T14:32:41Z","timestamp":1750084361000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.16141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,11]]},"references-count":43,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2017,5,9]]}},"alternative-id":["16141","28423727"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.16141","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,11]]}}}